Another humanized PD-L1 monoclonal antibody durvalumab (MEDI4736) with T cell dependent anti-tumor activity shows efficacy in the treatment of patients with urothelial carcinoma 72. This evidence concerns the gene CD274 and urothelial carcinoma.